文献速递类风湿关节炎

基线CDAI低疾病活动度范围与类风湿关节炎患者随时间出现的显著差异相关

The range of Clinical Disease Activity (CDAI) Low Disease Activity (LDA) at baseline is associated with marked differences with time in patients with Rheumatoid Arthritis (RA).
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-10-06

研究基于CorEvitas注册库,分析6856例基线CDAI处于缓解或低疾病活动度(0-10)的类风湿关节炎患者,比较基线CDAI 2.8-6(极低疾病活动度)与>6-10(高低疾病活动度)两组在1年和2年时进展为CDAI>10的比例及患者报告结局的差异。结果显示高低疾病活动度组预后较差,提示CDAI低疾病活动度定义可能过宽。

要点

  • 基线CDAI>6-10的高低疾病活动度患者1年和2年进展为CDAI>10的比例分别为31.2%和31.0%,显著高于2.8-6组的19.5%和19.6%。
  • 调整模型中,基线CDAI>6-10患者1年和2年处于中等疾病活动度的可能性几乎是2.8-6组的两倍。
  • CDAI低疾病活动度定义可能过宽,应将不同范围的低疾病活动度预后差异纳入治疗推荐。

核心结论

  • CDAI低疾病活动度定义可能过宽,包含预后较差的高低疾病活动度患者,应将这些差异纳入治疗推荐。

研究设计与样本

  • 使用CorEvitas注册库的基线和前瞻性随访数据,纳入6856例基线CDAI在0-10(缓解或低疾病活动度)的类风湿关节炎患者,分析基线CDAI范围与随时间变化的临床结局及患者报告结局的关系。

主要发现

  • 基线CDAI 2.8-6组1年和2年进展为CDAI>10的比例分别为19.5%和19.6%,基线CDAI>6-10组分别为31.2%和31.0%(p<0.001)。
  • 在粗模型和调整模型中,基线CDAI>6-10患者1年和2年处于中等疾病活动度的可能性几乎是2.8-6组的两倍。

关键数值与推荐

  • CDAI低疾病活动度范围为2.8-10,其中2.8-6为极低疾病活动度,>6-10为高低疾病活动度;缓解为CDAI 0-2.8。

临床怎么用

  • 临床评估RA患者低疾病活动度时,应区分CDAI 2.8-6与>6-10,后者预后较差,可能需要更积极的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to determine if the range of clinical outcomes across rheumatoid arthritis patients exposed to biologic, or JAK disease-modifying antirheumatic drugs (b/tsDMARDs) remained consistent with time using the low clinical disease activity index (CDAI;range of 2.8-10) and remission (CDAI 0-2.8), along with patient-reported outcomes (PROs). METHODS: We used baseline and prospective follow-up scores from the CorEvitas registry. All patients had measurement of the CDAI and validated PROs at baseline. We examined the evolution of these outcomes to determine if there were meaningful clinical differences with time based on the range of baseline CDAI scores. RESULTS: 6,856 patients with RA had baseline CDAI scores that were in CDAI Remission or LDA (0-10). 19.5% and 19.6% of patients whose baseline CDAI was between 2.8 and 6 ("very low" VLDA) vs. 31.2% and 31.0% of patients with a baseline CDAI >6-10 ("High LDA; HLDA) exhibited a CDAI >10 at 1 and 2 years respectively (p<0.001for change in CDAI from baseline in the LDA subgroups). In both crude and adjusted models, patients with a CDAI between >6 and 10 were almost twice as likely to have a CDAI in the moderate disease activity range at 1 and 2 years compared with patients in the range of 2.8-6. CONCLUSION: The definition of CDAI so-called low disease activity is likely overly broad and includes patients in the upper range of LDA with an inferior prognosis. These differences in outcomes across the range of LDA should be incorporated into therapeutic recommendations that recognize these disparate outcomes.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kremer JM, Kane K, Reed G, et al. The range of Clinical Disease Activity (CDAI) Low Disease Activity (LDA) at baseline is associated with marked differences with time in patients with Rheumatoid Arthritis (RA). Arthritis Care Res (Hoboken). 2026. PMID: 42839717. doi:10.1002/acr.80177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。